Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial ... (all TSX requirements for continued listi...)

Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid

Date:7/17/2009

all TSX requirements for continued listing, failing which the Share will be delisted from the TSX 30 days thereafter. The Corporation is, therefore, considering its options in this regard, which may include applying for a transfer of its listing to the TSX Venture Exchange or the NEX Board of the TSX Venture Exchange. Any decision in this regard will be made well in advance of the TSX deadline.

About Bradmer Pharmaceuticals Inc. (www.bradmerpharma.com)

Bradmer Pharmaceuticals' lead clinical candidate, Neuradiab, was developed at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain cancer, glioblastoma multiforme. Bradmer initiated enrollment of primary GBM patients in a Phase III multi-center clinical trial of Neuradiab. Neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency.

Bradmer Pharmaceuticals Inc.'s common shares have not been registered under the Securities Act of 1933, as amended (the "Securities Act") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regula
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. Bradmer announces 2009 first quarter operational and financial results
2. Bradmer announces 2008 fourth quarter and fiscal year operational and financial results
3. Bradmer implements cash conservation plan
4. Bradmer provides clinical trial update and announces evaluation of strategic alternatives
5. Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference
6. Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting
7. Bradmer announces 2008 third quarter operational and financial results
8. Bradmer to present at Rodman & Renshaw Healthcare Conference
9. Bradmer receives FDA approval to proceed with Phase III clinical trial
10. Bradmer announces 2008 first quarter operational and financial results
11. Bradmer announces new additions to management team

Post Your Comments:

(Date:12/15/2009)... being released by the American Health Information Management Association: ... CCS, FAHIMA ,, AHIMA President ,, ... On behalf of the A-H-I-M-A Board of Directors...it is ... officer, Doctor Alan Dowling... ,, Back last summer the ... we knew could effectively replace Linda Kloss ...

(Date:12/15/2009)... to a gynaecologist or midwife are generally associated ... could offer so much more. Women, doctors and ... opportunities for dialogue about sexual health, reveals a ... of Gothenburg, Sweden. , Many young women see ... 500 women aged 23-29 answered questions about their ...

(Date:12/15/2009)... Spanish scientists have found the first potential immunological clue ... by the pandemic H1N1 virus. , The study ... patients, 15 outpatients and 15 control subjects in 10 ... and August 2009. Researchers from the Hospital Clinico Universitario ... found high levels of a molecule called interleukin 17 ...

(Date:12/15/2009)... from their looks, and in what ways? A team ... University of Kansas found that yes; attractive people do ... increased sense of psychological well-being. This seems like common ... dollars each year trying to become more attractive. However, ... Personal Relationships , also determines that the importance of ...

(Date:12/15/2009)... Leading Workers, Compensation Carrier Confirms PMSI as Solution Provider ... ... Tampa, FL (Vocus) December 15, 2009 -- PMSI, ... providers of specialty products and services for the workers’ ... (KEMI) has decided to renew its pharmacy services (retail ...

Breaking Medicine News(10 mins):Health News:Dowling Press Availability Tuesday, December 15, 2009 / 10:00 a.m. CST 2 Health News:More about sex and relationships needed at gynecological visits 2 Health News:First immunological clue to why some H1N1 patients get very ill or die 2 Health News:The importance of attractiveness depends on where you live 2 Health News:KEMI Renews Contract With PMSI 2

[0] Dowling Press Availability Tuesday, December 15, 2009 / 10:00 a.m. CST [0] More about sex and relationships needed at gynecological visits [0] First immunological clue to why some H1N1 patients get very ill or die [0] The importance of attractiveness depends on where you live [0] KEMI Renews Contract With PMSI

... Provides Relief for Hangovers and Holiday Party Faux ... season brings a string of,parties and celebrations, the ... the line between fun and foolishness. This holiday,season, ... healthy,all-natural, caffeine-free hangover remedy to relieve the negative ...

... to help ... funds for childhood cancer, MEMPHIS, Tenn., Oct. 18 For ... finding cures and saving,children with pediatric cancer and other catastrophic childhood ... this,worthy cause by purchasing some of their favorite Procter and Gamble ...

... French . , A new study led by ... screening test is far more accurate than the traditional ... of the Canadian Cervical Cancer Screening Trial (CCCaST), led ... Cancer Epidemiology at McGill,s Faculty of Medicine, concluded that ...

... All-Cash Transaction Valued at US$26.00 Per Share -, ... (NASDAQ: ASPV ; TSX: ASV) today announced ... Galenica Group (SWX: GALN) under which,Galenica, through a ... shares at a price of US$26.00 per share ...

... to Testify Tonight at Fair Election Commission Hearing After CMC ... Silence in Response to Meeting Invitations, ... forming a union at Community Medical Centers are filing a ... CMC will,be notified today of the charges. Workers and ...

... American Heart,Association/American Stroke Association is pleased that President ... to Dr. Michael,DeBakey. The medal is the nation,s ... who pioneered coronary bypass surgery and,chancellor emeritus of ... Lifetime Achievement Award in 2004 and its Gold ...

Other Medicine News:Health News:Make a Toast, Not a Scene: Five Tips for the Holiday Office Party 2 Health News:Procter & Gamble Products Help Raise Funds, Awareness in Fight Against Childhood Cancer 2 Health News:Study: HPV test beats Pap in detecting cervical cancer 2 Health News:Study: HPV test beats Pap in detecting cervical cancer 3 Health News:Aspreva to be Acquired by Galenica For US$915 Million 2 Health News:Aspreva to be Acquired by Galenica For US$915 Million 3 Health News:Aspreva to be Acquired by Galenica For US$915 Million 4 Health News:Aspreva to be Acquired by Galenica For US$915 Million 5 Health News:Federal Charges Filed Against Community Medical Centers Management 2

Make a Toast, Not a Scene: Five Tips for the Holiday Office Party Procter & Gamble Products Help Raise Funds, Awareness in Fight Against Childhood Cancer Study: HPV test beats Pap in detecting cervical cancer Aspreva to be Acquired by Galenica For US$915 Million Federal Charges Filed Against Community Medical Centers Management American Heart Association Congratulates Pioneer Heart Surgeon for Being Named Recipient of Congressional Gold Medal Award

(Date:12/15/2009)... ,, Reportlinker.com announces that a new market ... ,, Hepatitis B Vaccines - Pipeline ... ,, http://www.reportlinker.com/p0167309/Hepatitis-B-Vaccines---Pipeline-Analysis-and-Market-Forecasts-to-2015.html ,, Hepatitis B ... to 2015 ,, Summary ,, ... "Hepatitis B Vaccines - Pipeline Analysis and ...

(Date:12/15/2009)... Dec. 15 Reportlinker.com announces ... is available in its catalogue: ,, ... assessment of the competitive environment is ... management responsibilities, the task crucial to ... and factual competitive intelligence is vital ...

(Date:12/15/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, The Future ... to 2015, Competitive Benchmarking, Product Pipeline ... http://www.reportlinker.com/p0168102/The-Future-of-HIV-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ,, Summary ... latest research "The Future of HIV ...

[0] Reportlinker Adds Hepatitis B Vaccines - Pipeline Analysis and Market Forecasts to 2015 [0] Reportlinker Adds Top Ten World's Leading Orthopedics Companies [0] Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis

... May 29 Magellan Biosciences, an,emerging leader ... and assays designed to streamline microbiology testing,and ... 108th meeting of the,American Society for Microbiology ... Technologies, will share booth 743 at the,exhibition, ...

... Wyeth,Pharmaceuticals, a division of Wyeth (NYSE: ... Drug Administration (FDA) has issued an approvable letter ... of,adult patients with community-acquired pneumonia (CAP)., Before ... analyses to support the safety and efficacy of ...

Other Medicine Technology:Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743 2 Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743 3 Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 2 Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 3 Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 4 Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 5 Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia 6

Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 743 Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia

Inquire...

500L...

... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...

Inquire...

Medicine Products:

Eppendorf Research Series 2100 Fixed-volume Pipette, 250 l Ovation BioNatural Pipette, one-stroke, fixed volume, 500L SoftGrip 500 L Fixed Volume Pipette Ovation BioNatural Pipette, two-stroke, fixed volume, 300L

Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial ...(all TSX requirements for continued listi...),Health